187
Participants
Start Date
December 28, 2017
Primary Completion Date
June 30, 2024
Study Completion Date
June 30, 2024
Hydroxychloroquine
Hydroxychloroquine is classified as an anti-malarial and it is has immunomodulatory functions that make it useful for treatment of autoimmune disorders including systemic lupus erythematosus and rheumatoid arthritis.
Placebo Oral Capsule
An oral capsule placebo is made to match the active intervention medication hydroxychloroquine.
Northwell Health, Great Neck
Penn State MS Hershey Medical Center, Hershey
Medical University of South Carolina, Charleston
Oklahoma Medical Research Foundation, Oklahoma City
UT Southwestern Medical Center, Dallas
University of Colorado Anschutz Medical Campus, Aurora
Cedars-Sinai Medical Center, Los Angeles
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Milton S. Hershey Medical Center
OTHER